A » Sourcing private label paracetamol capsules from a UK-based manufacturer to launch your own pharmacy brand requires meticulous attention to regulatory compliance, quality assurance, and commercial negotiation, given that paracetamol is a widely available over-the-counter analgesic subject to strict medicines legislation. First, you must ensure your business holds or partners with an entity that possesses the necessary licenses from the Medicines and Healthcare products Regulatory Agency (MHRA). As the brand owner, you will typically need a Manufacturer’s License (MIA) if you plan to perform any physical handling, or a Wholesale Dealer’s License (WDA(H)) if you only market and distribute; many new brands operate under a “third-party manufacturing” model where the contract manufacturer holds the MIA and the marketing authorisation (Product Licence) is obtained by your company or assigned to the manufacturer. The first step is to conduct a thorough search for UK-based contract manufacturers specialising in solid oral dosage forms, ideally those with MHRA-inspected facilities and experience in private labelling for the pharmacy sector. You can access the MHRA’s public register of licensed manufacturers or use industry directories such as the Association of the British Pharmaceutical Industry (ABPI) or the Contract Manufacturing Association. Once you have a shortlist, request a pre-qualification questionnaire to assess their capacity, validated processes for paracetamol capsule production, stability testing capabilities, and existing product dossiers—some manufacturers offer “off-the-shelf” formulations that can be customised with your brand name, design, and patient information leaflet (PIL) under a “white label” or “private label” agreement. You will then need to negotiate a quality agreement defining specifications (e.g., dissolution profile, impurity limits, excipient compatibility) and a supply agreement covering minimum order quantities, lead times, pricing, and confidentiality. Crucially, your new pharmacy brand must secure its own marketing authorisation (MA) from the MHRA for the specific paracetamol capsule product, which involves submitting an abridged application referencing a well-established product or a full dossier if you have a novel formulation. Alternatively, you may buy a “shelf company” that already holds a MA for paracetamol capsules, or enter a “licensing” arrangement where the manufacturer holds the MA and you operate as the Marketing Authorisation Holder (MAH) via a transfer. You will also need to design compliant packaging and PIL that meet the requirements of the Human Medicines Regulations 2012 and the Best Practice Guidance on Patient Information Leaflets. Consider appointing a Qualified Person (QP) who can certify batch release if your brand is the MAH, or rely on the manufacturer’s QP if your agreement permits. Additionally, you must register with the MHRA as a pharmaceutical wholesaler or distributor if you will store and supply the product directly to pharmacies. Finally, establish a pharmacovigilance system to report adverse reactions and ensure compliance with Good Distribution Practice (GDP) for storage and transport. Engaging a regulatory consultant with UK experience can streamline these steps, as the process from initial contact to first batch delivery typically takes six to eighteen months depending on formulation complexity and MHRA review times.